JPM
52
-3
FIS
46
-4
ZTS
23
-6
SE
50
-4
CMS
72
-2
CVS
62
4
TRV
50
-2
SYF
25
-5
EQT
82
-2
DIS
45
-5
CPB
42
-5
STI
8
-2
MPC
75
7
MET
37
5
SYK
42
-2
TGNA
66
-6
NI
77
-3
BA
36
3
D
38
-2
MCK
78
-2
JPM
52
-3
FIS
46
-4
ZTS
23
-6
SE
50
-4
CMS
72
-2
CVS
62
4
TRV
50
-2
SYF
25
-5
EQT
82
-2
DIS
45
-5
CPB
42
-5
STI
8
-2
MPC
75
7
MET
37
5
SYK
42
-2
TGNA
66
-6
NI
77
-3
BA
36
3
D
38
-2
MCK
78
-2
Financhill
Back

Arcus Biosciences, Inc. 10K Form

Buy
60

RCUS
Arcus Biosciences, Inc.

Last Price:
$23.93
Seasonality Move:
-4.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RCUS News And Ratings

See the #1 stock for the next 7 days that we like better than RCUS

RCUS Financial Statistics

Sales & Book Value

Annual Sales: $247M
Cash Flow: $-121M
Price / Cash Flow: 0
Annual Sales: $5.04
Price / Book: 4.69

Profitability

EPS (TTM): -3.30030
Net Income (TTM): $-353M
Gross Margin: $237M
Return on Equity: -67.06%
Return on Assets: -29.82%

Arcus Biosciences, Inc. Earnings Forecast

Key Arcus Biosciences, Inc. Financial Ratios

  • The Gross Profit Margin over the past 10 years for RCUS is 95.95%.
  • The Selling, General & Administrative Expenses for RCUS have been equal to 44.53% of Gross Profit Margin.
  • The Research & Development expenses have been 211.74% of Revenue.
  • The Net Earning history of RCUS is -142.91% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 2 years.

Arcus Biosciences, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Health Care
Current Symbol: RCUS
CUSIP: 03969F
Website: arcusbio.com

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 4.36
Quick Ratio: 4.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RCUS Technical Analysis vs Fundamental Analysis

Buy
60
Arcus Biosciences, Inc. (RCUS) is a Buy

Is Arcus Biosciences, Inc. a Buy or a Sell?